Corline Biomedical AB (CLBIO.ST)
SEK 8.76
(5.29%)
SEK 8.76
(5.29%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -3.85 Million SEK | -385700100.0% |
| 2022 | 1.00 SEK | 100.0% |
| 2021 | -889 Thousand SEK | -88900100.0% |
| 2020 | 1.00 SEK | 0.0% |
| 2019 | 1.00 SEK | 100.0% |
| 2018 | -324 Thousand SEK | -710.0% |
| 2017 | -40 Thousand SEK | -4000100.0% |
| 2016 | 1.00 SEK | 0.0% |
| 2015 | 1.00 SEK | 100.0% |
| 2014 | -116.75 Thousand SEK | -11675100.0% |
| 2013 | 1.00 SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | 100.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q3 | 1.00 SEK | 0.0% |
| 2023 Q4 | -3.85 Million SEK | -385700100.0% |
| 2023 FY | -3.85 Million SEK | -385700100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2022 Q1 | -2.7 Million SEK | -17.65% |
| 2022 Q4 | 1.00 SEK | 0.0% |
| 2022 Q3 | - SEK | 100.0% |
| 2022 FY | 1.00 SEK | 100.0% |
| 2022 Q2 | -2.13 Million SEK | 20.81% |
| 2021 FY | -889 Thousand SEK | -88900100.0% |
| 2021 Q3 | 1.00 SEK | 0.0% |
| 2021 Q4 | -2.29 Million SEK | -229500100.0% |
| 2021 Q1 | -1.21 Million SEK | -121200100.0% |
| 2021 Q2 | 1.00 SEK | 100.0% |
| 2020 Q1 | 1.00 SEK | 0.0% |
| 2020 FY | 1.00 SEK | 0.0% |
| 2020 Q3 | -270 Thousand SEK | -27000100.0% |
| 2020 Q4 | 1.00 SEK | 100.0% |
| 2020 Q2 | 1.00 SEK | 0.0% |
| 2019 Q2 | 1.00 SEK | 100.0% |
| 2019 FY | 1.00 SEK | 100.0% |
| 2019 Q4 | 1.00 SEK | 100.0% |
| 2019 Q3 | -137 Thousand SEK | -13700100.0% |
| 2019 Q1 | -95 Thousand SEK | 70.68% |
| 2018 Q2 | - SEK | -100.0% |
| 2018 Q3 | -70 Thousand SEK | 0.0% |
| 2018 Q4 | -324 Thousand SEK | -362.86% |
| 2018 FY | -324 Thousand SEK | -710.0% |
| 2018 Q1 | 1.00 SEK | 0.0% |
| 2017 Q3 | -20 Thousand SEK | 55.56% |
| 2017 Q2 | -45 Thousand SEK | -4500100.0% |
| 2017 Q1 | 1.00 SEK | 0.0% |
| 2017 Q4 | 1.00 SEK | 100.01% |
| 2017 FY | -40 Thousand SEK | -4000100.0% |
| 2016 FY | 1.00 SEK | 0.0% |
| 2016 Q4 | 1.00 SEK | 0.0% |
| 2016 Q3 | 1.00 SEK | 0.0% |
| 2016 Q2 | 1.00 SEK | 100.0% |
| 2016 Q1 | -169.49 Thousand SEK | -16949700.0% |
| 2015 Q4 | 1.00 SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 FY | 1.00 SEK | 100.0% |
| 2014 FY | -116.75 Thousand SEK | -11675100.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2013 FY | 1.00 SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | 192850100.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 7.926% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 45.95% |
| Mendus AB (publ) | - SEK | Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 125.877% |
| Intervacc AB (publ) | 10.48 Million SEK | 136.793% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | -154180.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 110.948% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 142.534% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -197694.872% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 222.444% |
| Saniona AB (publ) | 1.00 SEK | 385700100.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | -137.208% |
| Biovica International AB (publ) | 2.19 Million SEK | 275.398% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 385700100.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 285.433% |
| Xintela AB (publ) | 398 Thousand SEK | 1069.095% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 651.0% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | -346.93% |
| Amniotics AB (publ) | 534 Thousand SEK | 822.285% |
| 2cureX AB (publ) | -1000.00 SEK | -385600.0% |
| CombiGene AB (publ) | -1.79 Million SEK | -114.397% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 118.881% |
| Camurus AB (publ) | 100.95 Million SEK | 103.821% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 385800.0% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| I-Tech AB | 4.28 Million SEK | 190.117% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 139.389% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 21.749% |
| Cantargia AB (publ) | - SEK | Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 807.399% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 108.81% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | -762.891% |
| Nanologica AB (publ) | 2.97 Million SEK | 229.734% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | -1101.015% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 132.565% |
| Alzinova AB (publ) | -3.27 Million SEK | -17.663% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 259.052% |
| Pila Pharma AB (publ) | 1.00 SEK | 385700100.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -259455.855% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 195.612% |
| Simris Alg AB (publ) | 1.09 Million SEK | 453.529% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 116.037% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 103.61% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 475.195% |